3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
4
Active not recruiting
4
Terminated
3
Unknown
2
Recruiting
2
Withdrawn
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
28
Gynecologic
6
Gastrointestinal
6
Other solid neoplasm
5
Tumor-Agnostic
3
CNS
3
Thoracic
2
Sarcoma
2
Plasma cell
2
Lymphoid
2
Genitourinary
2
Other hematologic neoplasm
1
Head & Neck
1
Dermatologic
1
Conditions
Carcinoma, Renal Cell
2
von Hippel-Lindau Disease
1
Kidney Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
87
Specimen Handling
76
pembrolizumab
74
enzalutamide
57
Radiosurgery
57
Radiotherapy
51
Docetaxel
50
Androgen Antagonists
48
Gemcitabine
43
Nivolumab
40
darolutamide
39
Prednisone
35
Abiraterone Acetate
33
enfortumab vedotin
32
Biopsy
31
Cisplatin
30
Carboplatin
29
apalutamide
28
Standard of Care
28
cabozantinib
27
Pluvicto
27
abiraterone
26
Blood Specimen Collection
25
Radiation
23
Leuprolide
23
Ipilimumab
23
X-Rays
18
relugolix
17
Triptorelin Pamoate
17
Surveys and Questionnaires
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
palbociclib
×
Genitourinary
×
Clear all
NCT07405164
2026-05-29
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3
Recruiting
450 enrolled
NCT07123090
2026-03-25
SPARCC
Dana-Farber Cancer Institute
Phase 2
Recruiting
25 enrolled